Current Edition

New Hampshire Pharmaceutical Development and Clinical Manufacturing Facility Nears Completion

SGS Will Open Its New Facility Near Boston, MA, in August 2022

In August 2022,  SGS’s Quay Pharma – our global Center of Excellence for Formulation and Clinical Manufacturing – will open its new Hudson, NH, site located 40 miles outside of Boston. The 55,000 sq. ft. pharmaceutical development and clinical manufacturing facility is almost ready for business, with 90% of the clean rooms having already been built.

The facility’s capabilities

The new facility will consist of analytical and formulation labs as well as GMP manufacturing space. Our staff will support the development of drug products, providing much-needed assistance to help organizations successfully bring products for oral and topical delivery to market.

Our staff will also leverage its expertise to progress projects involving small molecules and the oral and topical delivery of biologicals (including live biotherapeutics and other microbiome-based therapeutics). Over the next three years, the site will create more than 100 jobs.

Excellence in formulation development and specialist clinical manufacturing

Since opening its doors in 2002, SGS’s Quay Pharma has carved out a reputation for excellence in formulation development and specialist clinical manufacturing. It has successfully completed over 300 successful projects for a global client base from out of its existing UK-based MHRA- and FDA-inspected facility. Having acquired Quay Pharma back in late 2021, we are committed to extending its global reach and capacity moving forward. For example, by opening this new facility close to Boston.

Maireadh Pedersen, SGS’s Quay Pharma’s Commercial Operations Director, commented:

“This is an extremely exciting and at the same time a natural move for the company, as we have been working with a great many US clients for several years and have built up a strong and growing customer base in the country.

Customers will benefit from our ability to support them from either location. Our understanding of the regulatory difference between the EU and the US will enable us to build the groundwork for the relevant quality requirements at an early stage. This allows our customers to efficiently transition through the clinical phases as they expand their clinical trial sites around the world.

The Greater Boston facility will be one of the first facilities established in the US for the development and manufacture of live biotherapeutic finished dosages and SGS will be the first company to support this type of manufacture for microbiome-based medicines in both Europe and the US.”

For further information, please contact:

David Humphreys 
Head of Preclinical Business Development at SGS
t: +44 (0)7570 649 047

About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 96,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world